How does Homopeptide compare to Shanghai Wibson Biotechnology on documentation quality?

Details up front: Homopeptide · Shanghai Wibson Biotechnology.

I would like the axes of comparison first and the recommendation second.

I have tried the first option and it works; the question is whether the second is better rather than merely different.

Is there a defensible reason to prefer one, or is this a coin flip?

A single member running three suppliers on one method is worth more than thirty members running one supplier each.

Publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.

Certificate red flags and what each implies

Worth being precise here: sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.

Gradient slope, column chemistry and detection wavelength all affect the reported purity figure, which is why the method section is the part that makes results comparable.

Comparisons drawn from different laboratories at different times are weaker evidence than most people treat them as.

Name the laboratory and the dates or the comparison cannot be reproduced.

Specifically, this is the question where methodology matters more than the conclusion.

Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.

Lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.

The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.

No supplier on this site pays for its position, and the storefront links are marked nofollow and sponsored.

Use a fixed documentation checklist rather than an impression.

Answer first: comparing suppliers is only meaningful if the comparison holds the laboratory, the method and the compound constant, and most published comparisons hold none of them.

Submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.

To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.

Inter-laboratory spread on identical peptide material is routinely half a per cent to a per cent by RP-HPLC, which is the noise floor for any cross-laboratory comparison.

One laboratory, one method, one submission. Otherwise it is not a comparison.

edited 22 Oct 2024 by ilaria_bertone — expanded the table to cover the lower concentration

The short version: same compound, same laboratory, same method, ideally same week — otherwise you are comparing laboratories rather than suppliers.

Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.

Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.

Price per milligram of measured peptide, not per milligram of label claim.

The relevant detail is that ratings on this site are ours alone and are deliberately not reconciled with anyone else's.

Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Compare content, not purity. Purity clusters and content does not.